Navigation Links
Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
Date:6/8/2012

V1). The secondary objective was to assess pulmonary exacerbation rates for ataluren compared to placebo. Additional endpoints evaluated other aspects of patient function, drug activity, and safety. The 48-week trial enrolled 238 patients, ages six years and older, at multiple sites in North America, Europe, and Israel. Patients were randomly assigned to one of two treatment arms: ataluren (10 mg/kg morning, 10 mg/kg midday, 20 mg/kg evening) or placebo (morning, midday, evening). Patients who completed the study were eligible to receive open-label ataluren in an ongoing extension study. 

About AtalurenAn investigational new drug, ataluren is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein. The resulting disorder is determined by which protein cannot be expressed in its entirety and is no longer functional, such as the cystic fibrosis transmembrane conductance regulator protein (CFTR) in nmCF.

The FDA and the European Commission have granted ataluren Orphan Drug status for the treatment of nonsense mutation cystic fibrosis and nonsense mutation Duchenne and Becker muscular dystrophy. The FDA has also granted ataluren Subpart E designation for expedited development, evaluation, and marketing for CF and dystrophinopathy and Fast Track designation for the development of treatment for nonsense mutation dystrophinopathy.

The development of ataluren has been supported by grants from Cystic Fibrosis Foundation Therapeutics Inc. (the nonprofit affiliate of the Cystic Fibrosis Foundation); Muscular Dystrophy Association; FDA's Office of Orphan Products Development; National Center for Research Resources; National Heart, Lung, and Blood Institute; and Parent Project Muscular Dystrophy.

About PTC Therapeutics, Inc.<
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
2. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
3. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
4. Sorrento Therapeutics Awarded Third Phase I STTR Grant
5. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
6. Interim Results Reported for Phase I Open-Label Clinical Trial for the Treatment of PTSD and MDD Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
7. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
8. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
9. Preliminary Phase 2 Data of Ocera Therapeutics OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction
10. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
11. Clinilabs Opens Phase I Unit In Eatontown, New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  Now available for sale, The Armor1 Ankle Roll ... ankle sprains by cushioning the ankle from an inversion ... the outside of any shoe type and allows the ... offering protection against sprains. With customers in physical therapy, ...
(Date:1/23/2015)... 2015 Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC ...  filed a Preliminary Proxy Statement, Schedule 14A, with the U.S. ... an update for shareholders detailing why a "YES" vote to ... Dear Shareholders, As we reflect upon the 2014 ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... June 28 Tolerx, Inc., a biopharmaceutical company ... by modulating T cell activity, today announced the initiation ... evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The ... Therapy Evaluation For Early or New-Onset Type 1 Diabetes) ...
... 2010 , , , ... 3D Images Provide New Approach to Monitoring Bone Changes , ... Interim data from a prospective Investigator Initiated Trial (IIT),presented ... demonstrates that EVISTA(R) (raloxifene 60mg;,once-daily, distributed in 34 countries by DAIICHI SANKYO), indicated for ...
Cached Medicine Technology:Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes 2Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes 3Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes 4New High-Resolution Computer Tomography Data Demonstrates EVISTA(R)'s Effect on Bone Quality in Osteoporotic Patients 2New High-Resolution Computer Tomography Data Demonstrates EVISTA(R)'s Effect on Bone Quality in Osteoporotic Patients 3New High-Resolution Computer Tomography Data Demonstrates EVISTA(R)'s Effect on Bone Quality in Osteoporotic Patients 4New High-Resolution Computer Tomography Data Demonstrates EVISTA(R)'s Effect on Bone Quality in Osteoporotic Patients 5
(Date:1/22/2015)... 22, 2015 Deer Path of Huntley ... Valentine’s Day Happy Hour from 3 p.m. to 4 p.m. on ... Parkway in Huntley, Illinois, serves adults with physical disabilities between the ... include Valentine's Day treats, games and sweetheart-themed karaoke. , For more ...
(Date:1/22/2015)... 22, 2015 Liberty University has received accreditation ... program from the Council for Accreditation of Counseling & ... Liberty’s Center for Counseling & Family Studies , is ... the university’s new School of Behavioral Sciences. Prior to the ...
(Date:1/22/2015)... The City of West Hollywood hosted a news conference on ... anniversary of the Supreme Court decision Roe v. Wade, which legalized ... the Roe vs. Wade decision and the fight to protect a ... City of West Hollywood Councilmember Abbe Land. “We need to continue ...
(Date:1/22/2015)... January 22, 2015 Gabe’s Chemo Duck Program is ... the first app ever created for kids with cancer. The Chemo ... and devices, is filled with enjoyable games to help children of ... The free app helps to keep kids entertained, educated and at ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 VogueQueen is a ... affordable prices and many designers are thrilled to have it ... business announces its new collection of prom dresses for the ... to drive the strategic vision and he focuses on continuing ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2
... products. Same flavors. Fewer caloriesFORT WORTH, Texas, ... the Hispanic baking industry by becoming the ... line of 100 Calorie products. Building on ... the 100 Calorie line offers the perfect ...
... new study suggests , , MONDAY, Feb. 16 (HealthDay News) -- ... sleep it off, but they run the risk of developing ... cycle of headaches, a new study shows. , "Going to ... treat their headaches, and they rated it a very effective ...
... LLC, the nation,s leading provider of telemedicine health ... offshore medical service that connects remote workers with ... combines advanced telemedicine technology and medical services to ... Offshore rig and remote workers gain access to ...
... ARLINGTON, Texas, Feb. 16 Across the nation, countless ... executives at one North Texas healthcare company took some ... from being another victim to the economic crisis.2009 looks ... now in its 7th year. One year ago ten ...
... their electroplating, anodizing, and electropolishing plant. , ... Toccoa, ... completion of their new 16, long, 27 station aluminum anodizing line. ... works for some time now and even though the economy is ...
... screening, they say , , MONDAY, Feb. 16 ... screening and diagnostic for breast cancer, not serve as ... guidelines. , The guidelines, published Monday in the ... give needed direction for using breast MRI, a relatively ...
Cached Medicine News:Health News:Marinela USA(R) Launches 100 Calorie Product Line 2Health News:Using Sleep to Manage Headaches May Cause Insomnia 2Health News:Using Sleep to Manage Headaches May Cause Insomnia 3Health News:InPlace Medical Solutions Announces Advanced Medical Services for Offshore and Remote Locations 2Health News:InPlace Medical Solutions Announces Advanced Medical Services for Offshore and Remote Locations 3Health News:InPlace Medical Solutions Announces Advanced Medical Services for Offshore and Remote Locations 4Health News:InPlace Medical Solutions Announces Advanced Medical Services for Offshore and Remote Locations 5Health News:InPlace Medical Solutions Announces Advanced Medical Services for Offshore and Remote Locations 6Health News:InPlace Medical Solutions Announces Advanced Medical Services for Offshore and Remote Locations 7Health News:InPlace Medical Solutions Announces Advanced Medical Services for Offshore and Remote Locations 8Health News:InPlace Medical Solutions Announces Advanced Medical Services for Offshore and Remote Locations 9Health News:InPlace Medical Solutions Announces Advanced Medical Services for Offshore and Remote Locations 10Health News:Staying Healthy in 2009 2Health News:Experts Release Guidelines on Use of Breast MRI 2
... Ulti-Mist™ HME product line has the right ... to adults and from intubated patients to ... humidification for both anesthesia and critical care ... provide maximum protection for patients and staff ...
... HME product line has the right product ... adults and from intubated patients to patients ... for both anesthesia and critical care applications., ... maximum protection for patients and staff members. ...
... (HCH) capture the patient`s exhaled heat and ... gas. Small and compact, they are specially ... Depending on the tidal volume requirements, select ... ,The adult HCH is ideal for patient ...
... capture the patient`s exhaled heat and moisture ... Small and compact, they are specially treated ... on the tidal volume requirements, select either ... adult HCH is ideal for patient tidal ...
Medicine Products: